Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | IDE | P14735 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.71 |
| ▸ | HLCS | P50747 | 6/20 | 0.64 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | NR2E3 | Q9Y5X4 | 2/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19170150 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL10047674 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL10047701 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL565879 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL10171691 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL19267509 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL20216901 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL21488759 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL20844951 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL14617995 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107515-A1 | INCRETIN HORMONE COMPOSITIONS AND METHODS USING SAME | DIASOME PHARMACEUTICALS, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | DIASOME PHARMACEUTICALS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | claimed |
| CN-119395003-A | Kit, microfluidic device and method for performing biotin assays | 美国西门子医学诊断股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| US-20250027947-A1 | KITS, MICROFLUIDICS DEVICES, AND METHODS FOR PERFORMING BIOTIN ASSAYS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-01-23 | — | — | US | claimed |
| CN-112424589-B | Kit, microfluidic device and method for performing biotin assays | 美国西门子医学诊断股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| EP-3830556-B1 | KITS, MICROFLUIDICS DEVICES, AND METHODS FOR PERFORMING BIOTIN ASSAYS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2024-11-13 | — | — | EP | claimed |
| US-12140596-B2 | Kits, microfluidics devices, and methods for performing biotin assays | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2024-11-12 | — | — | US | claimed |
| WO-2024182425-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES/DISORDERS | NOUREDDINE ACHRAF (US) | 2024-09-06 | — | — | WO | claimed |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. | 2010-05-27 | — | — | US | claimed |
| WO-2009042945-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION ) (US) | 2009-04-02 | — | — | WO | claimed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | claimed |
| CN-101237854-A | Lipid construct for delivery of insulin to a mammal | SDG INC (US) | 2008-08-06 | — | — | CN | claimed |
| CN-101237855-A | Lipid construct for delivery of interferon to a mammal | SDG INC (US) | 2008-08-06 | — | — | CN | claimed |
| EP-1883394-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | claimed |
| EP-1883395-A2 | LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, Inc. (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2006127361-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| WO-2006127360-A2 | LIPID CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| EP-0088542-B1 | SKIN TREATMENT COMPOSITION | UNILEVER N.V. (NL) | 1988-05-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | HAVCR2, IFNAR1, IFNG | TDP1 4713/4885L3MBTL1 3129/4885MEN1 4095/4885 |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | TDP1 4819/4885L3MBTL1 3625/4885MEN1 966/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | TDP1 4755/4885L3MBTL1 3724/4885MEN1 2415/4885 |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | GPR119, INSR, FABP1 | TDP1 4833/4885L3MBTL1 2520/4885MEN1 2073/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4757/4885L3MBTL1 2707/4885MEN1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.